Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST trial of oral ZPL389 in moderate to severe atopic dermatitis
2017-002176-75Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ZPL389 dose-ranging arms with Placebo (2 arms). Primary endpoint: Investigator's Global Assessment response at week 16. Started Jan 2018; status: terminated.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-002176-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002176-75.